Of note, a piperidine derivative targeting EZH2 (enhancer of zeste homologue 2) has been reported to reduce GBM cell viability and impair tumor development and aggressiveness via an immunomodulatory mechanism [56]. This evidence concerns the gene EZH2 and neoplasm.